

# Press Release

Regulated information

## DISCLOSURE OF ACQUISITION OF TREASURY SHARES

Waregem (Belgium) / Rotterdam (the Netherlands)<sup>1</sup>, 7 March 2013 – Arseus discloses the information with respect to the acquisition of treasury shares required under Article 207 of the Royal Decree of 30 January 2001 implementing the Belgian Company Code.

Arseus today announces that during the period from 27 February to 7 March 2013, it acquired 40,512 treasury shares on NYSE Euronext Brussels (through an intermediate, acting with a discretionary mandate).

Acquisition date	Number of shares	Average price	Lowest price	Highest price	Amount
27 February 2013	13,374	€ 19.6024	€ 19.40	€ 19.65	€ 262,162
28 February 2013	15,000	€ 19.9852	€ 19.88	€ 20.22	€ 299,778
1 March 2013	3,144	€ 19.9608	€ 19.89	€ 20.13	€ 62,757
5 March 2013	1,368	€ 20.3028	€ 20.26	€ 20.34	€ 27,774
6 March 2013	4,004	€ 20.3547	€ 20.40	€ 20.47	€ 81,500
7 March 2013	3,622	€ 20.3973	€ 20.30	€ 20.49	€ 73,879

In addition, during the period from 27 February to 7 March 2013, Arseus acquired 102,875 treasury shares via various block trades.

Acquisition date	Block	Price	Amount
27 February 2013	10,000	€ 19.5800	€ 195,800
27 February 2013	7,500	€ 19.6300	€ 147,225
28 February 2013	15,000	€ 20.1000	€ 301,500
28 February 2013	20,000	€ 19.9700	€ 399,400
28 February 2013	40,375	€ 19.9500	€ 805,481
7 March 2013	10,000	€ 20.3800	€ 203,800

<sup>1</sup> This press release was sent out by Arseus NV and Arseus BV.

The Extraordinary Shareholders' Meeting held on 16 June 2009 renewed the authorisation of the Board of Directors to acquire treasury shares.

Prior to the transactions, Arseus already held 651,775 treasury shares. As a result of the transactions referred to above, Arseus now holds 795,162 treasury shares, representing 2.54% of the total number of shares outstanding.

*In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.*

**For more information:**

Constantijn van Rietschoten  
Director of Corporate Communications  
+31 88 33 11 222 (Office)  
+31 6 536 91 585 (Mobile)  
[constantijn.van.rietschoten@arseus.com](mailto:constantijn.van.rietschoten@arseus.com)

Veronique Lefel  
Investor Relations Officer  
+31 88 33 11 213 (Office)  
+31 6 105 77 754 (Mobile)  
[veronique.lefel@arseus.com](mailto:veronique.lefel@arseus.com)

**Arseus profile**

Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in 28 countries in Europe, North America, South America, Asia and Australia. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical ICT-solutions. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.